Benvegnù L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A
Clinica Medica Second, University of Padova, Italy.
Hepatology. 1997 Jan;25(1):211-5. doi: 10.1053/jhep.1997.v25.pm0008985292.
The influence of the hepatitis C virus (HCV)-genotype on liver disease severity was evaluated in 429 consecutive patients with chronic hepatitis C, including 109 with cirrhosis who were followed up prospectively, allowing for the assessment of the role of the HCV-genotype on disease outcome and on the development of hepatocellular carcinoma (HCC). HCV-1 was detected in 147 (46%) patients without cirrhosis and in 47 (43%) with cirrhosis (P: not significant), being mainly HCV-1b. HCV-2 was found in 103 (32%) cases without cirrhosis and in 30 (27.5) with cirrhosis (P: not significant), being mainly HCV-2a. HCV-3 was detected in 32 (10%) patients without cirrhosis and in 2 (2%) with cirrhosis (P < 0.005). Infection with more than one genotype (HCV-1/HCV-2 and HCV-1/HCV-3) was observed only in cirrhotic patients (6 of 109; 5.5%). During a mean follow-up of 67 +/- 22 months, 21 (19%) patients with cirrhosis showed worsening in Child's stage, 5 (4.5%) underwent liver transplantation, 23 (21%) developed HCC, and 24 (22%) died of complication of liver disease; the overall incidence of at least one of these events was 38.5%. By the Kaplan-Meier method and log-rank test, the cumulative probability of developing each or at least one of the above events did not differ in relation to the genotype of infecting HCV, apart from patients with mixed genotype infection who showed a significantly higher incidence of death (P < .05). These data indicate that HCV-genotypes do not have a significant effect on the severity and outcome of liver disease in patients with chronic HCV-infection. Patients with cirrhosis who are also infected by HCV-1 and HCV-2 had a similar prognosis and progression to HCC, while patients infected by more than one genotype showed the most unfavorable course of disease.
在429例慢性丙型肝炎患者中评估了丙型肝炎病毒(HCV)基因型对肝病严重程度的影响,其中包括109例肝硬化患者,对其进行了前瞻性随访,从而能够评估HCV基因型在疾病转归以及肝细胞癌(HCC)发生中的作用。在147例(46%)无肝硬化患者及47例(43%)肝硬化患者中检测到HCV-1(P:无显著性差异),主要为HCV-1b。在103例(32%)无肝硬化病例及30例(27.5%)肝硬化病例中发现HCV-2(P:无显著性差异),主要为HCV-2a。在32例(10%)无肝硬化患者及2例(2%)肝硬化患者中检测到HCV-3(P<0.005)。仅在肝硬化患者中观察到感染一种以上基因型(HCV-1/HCV-2和HCV-1/HCV-3)(109例中的6例;5.5%)。在平均67±22个月的随访期间,21例(19%)肝硬化患者的Child分期恶化,5例(4.5%)接受了肝移植,23例(21%)发生了HCC,24例(22%)死于肝病并发症;这些事件中至少发生一项的总发生率为38.5%。通过Kaplan-Meier法和对数秩检验,除混合基因型感染患者的死亡发生率显著较高(P<.05)外,发生上述每种事件或至少一种事件的累积概率与感染HCV的基因型无关。这些数据表明,HCV基因型对慢性HCV感染患者肝病的严重程度和转归没有显著影响。同时感染HCV-1和HCV-2的肝硬化患者具有相似的预后和向HCC的进展,而感染一种以上基因型的患者疾病进程最不利。